Very low dose of flutamide in the treatment of hyperandrogenism

A molecularly imprinted poly 2-aminophenol-gold nanoparticle-reduced graphene oxide composite for electrochemical determination of flutamide in environmental and biological samples

A selective and sensitive electrochemical sensor based on reduced graphene oxide, gold nanoparticles, and molecularly imprinted poly 2-aminophenol was developed for electrochemical determination of flutamide in environmental and biological samples. The composite fabrication was electrochemically carried out and the composite was characterized by Fourier transform infrared, proton and carbon nuclear magnetic resonance, field emission scanning electron microscopy, and energy-dispersive X-ray spectrometry. The spectroscopic results showed that polymerization of molecularly imprinted poly 2-aminophenol took place through a ladder structure system. After optimization of effective parameters on the response of the sensor, the obtained linear range, relative standard deviation (for a concentration of 50 μg L^-1 with five replicates) and limit of quantification for flutamide determination were determined to be 2-375 μg L^-1, 1.54% and 0.8 μg L^-1, respectively. The results showed that the application of poly 2-aminophenol in the structure of the proposed sensor using a molecular imprinting approach made the sensor highly selective toward flutamide, distinguishing it from similar nitro-containing compounds. The prepared sensor was successfully utilized to analyze environmental water and urine samples. The obtained results showed that the proposed method is in agreement with the HPLC method and can be used as a reliable alternative method for the analysis of flutamide.

In Search of New Therapeutics-Molecular Aspects of the PCOS Pathophysiology: Genetics, Hormones, Metabolism and Beyond

In a healthy female reproductive system, a subtle hormonal and metabolic dance leads to repetitive cyclic changes in the ovaries and uterus, which make an effective ovulation and potential implantation of an embryo possible. However, that is not so in the case of polycystic ovary syndrome (PCOS), in which case the central mechanism responsible for entraining hormonal and metabolic rhythms during the menstrual cycle is notably disrupted. In this review we provide a detailed description of the possible scenario of PCOS pathogenesis. We begin from the analysis of how a set of genetic disorders related to PCOS leads to particular malfunctions at a molecular level (e.g., increased enzyme activities of cytochrome P450 (CYP) type 17A1 (17α-hydroxylase), 3β-HSD type II and CYP type 11A1 (side-chain cleavage enzyme) in theca cells, or changes in the expression of aquaporins in granulosa cells) and discuss further cellular- and tissue-level consequences (e.g., anovulation, elevated levels of the advanced glycation end products in ovaries), which in turn lead to the observed subsequent systemic symptoms. Since gene-editing therapy is currently out of reach, herein special emphasis is placed on discussing what kinds of drug targets and which potentially active substances seem promising for an effective medication, acting on the primary causes of PCOS on a molecular level.

The diagnosis and treatment of PCOS in adolescents: an update

PURPOSE OF REVIEW

Polycystic ovary syndrome (PCOS) is often difficult to diagnose in adolescents. Recent recommendations and concepts regarding the diagnosis and treatment of PCOS in the adolescent girl are considered.

RECENT FINDINGS

The diagnosis of PCOS in adolescents should be primarily based on clinical and biochemical signs of hyperandrogenism and presentation with irregular menses. Because of the similarity of normal pubertal development and features of PCOS, the diagnosis should be deferred until at least 2 years following menarche. For girls who do not fulfill the diagnostic criteria, the focus should be on treatment of symptoms.

SUMMARY

PCOS is a complex, multifaceted disorder, and should be diagnosed and treated in adolescents after taking into consideration the patient's full diagnostic picture, metabolic risks, and individual concerns, to both avoid overdiagnosis but yet be able to provide early and meaningful interventions.